Latest Security News

Spheria Emerging Companies Limited has reported a solid 16.8% increase in profit after tax for the half-year ending December 2025, alongside a strategic shift introducing monthly fully franked dividends.

MEC Resources Ltd reported a half-year loss of $431,971 amid ongoing legal challenges over key gas exploration permits, while progressing investments in clean energy and neurotechnology. The company also completed a $359K options placement, reinforcing its financial position.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Glennon Small Companies Limited reported a half-year loss for the period ending 31 December 2025, driven by significant investment portfolio losses. Despite this, the company declared dividends and extended a key convertible loan.

Alcoa of Australia has partnered with the federal government to overhaul the environmental approvals process for its Western Australian mining operations, committing $55 million to conservation efforts and securing operational certainty through 2045.

AuMEGA Metals has successfully upsized its institutional financing to C$30.1 million, anchored by Condire Investors who will hold nearly 20% of the company. The funds will accelerate exploration programs across its Newfoundland gold projects.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Kaili Resources has reported encouraging initial pXRF results from its latest aircore drilling campaign targeting rare earth elements in South Australia's Mallee Project. Full assay results are pending, setting the stage for expanded exploration.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.